Topic Hub
25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 25 of 25 clinical reviews.
A physician-reviewed deep dive into PT-141 (bremelanotide), its melanocortin mechanism, the RECONNECT trial data, and evidence-based muscle preservation strategies for patients using or considering this peptide.
Read clinical reviewDoes PT-141 (bremelanotide) change appetite or food cravings? A physician-reviewed deep dive into the melanocortin pharmacology, RECONNECT trial data, nausea mechanisms, and clinical management guidance.
Read clinical reviewA physician-level review of bremelanotide (PT-141) use in patients with autoimmune conditions, covering mechanism, immunomodulatory evidence, cardiovascular precautions, drug interactions, and practical dosing guidance.
Read clinical reviewA clinician-level review of what bremelanotide does and does not do to bone mineral density, covering melanocortin receptor biology, the RECONNECT trial data, and practical monitoring guidance for prescribers.
Read clinical reviewA physician-level review of the cancer risk data for PT-141 (bremelanotide), covering preclinical findings, RECONNECT trial safety, FDA label warnings, and what the current evidence does and does not show.
Read clinical reviewA physician-reviewed deep dive into the cardiovascular effects of PT-141 (bremelanotide), covering blood pressure, heart rate, long-term safety, and clinical guidance from the RECONNECT trials and FDA label.
Read clinical reviewA physician-reviewed deep dive into how PT-141 (bremelanotide) affects cognitive function, mood, and CNS activity, with primary-literature citations, real trial data, and clinical guidance.
Read clinical reviewA physician-level comparison of compounded PT-141 versus FDA-approved Vyleesi (bremelanotide), covering pharmacology, clinical trial data, dosing, safety, cost, and how to choose the right formulation.
Read clinical reviewA GRADE-graded review of every major clinical trial and guideline behind bremelanotide (PT-141), written at MD/PharmD depth with inline citations to primary literature.
Read clinical reviewA physician-level review of every documented dermatologic effect of bremelanotide (PT-141), including flushing, hyperpigmentation, and what the RECONNECT trial data say about hair changes.
Read clinical reviewA physician-reviewed, evidence-based review of how PT-141 (bremelanotide) affects liver function, including hepatic metabolism, transaminase data from RECONNECT, and clinical monitoring guidance.
Read clinical reviewA clinician-reviewed deep dive into how bremelanotide affects mood, anxiety, depression, and psychological well-being in women with HSDD, with primary-literature citations and dosing guidance.
Read clinical reviewA clinician-level review of how bremelanotide (PT-141) is metabolized, its effects on energy expenditure and thermogenesis, pharmacokinetics, and what the RECONNECT trial data mean for clinical practice.
Read clinical reviewA clinician-level review of PT-141 (bremelanotide) microdosing protocols, standard FDA-approved dosing, the RECONNECT trial data, and how telehealth prescribers are approaching off-label low-dose use for HSDD and ED.
Read clinical reviewA clinician-level guide to diagnosing and resolving PT-141 (bremelanotide) plateau and non-response, with primary-literature citations, dosing strategies, and a structured decision framework.
Read clinical reviewA clinician-level review of bremelanotide (PT-141) use after bariatric surgery, covering pharmacokinetics, dosing adjustments, safety, and RECONNECT trial data for post-bariatric HSDD management.
Read clinical reviewHow long before surgery must PT-141 (bremelanotide) be stopped? This MD/PharmD-level guide covers the recommended hold window, cardiovascular and hemodynamic risks, anesthesia interactions, and how to restart after surgery.
Read clinical reviewA physician-reviewed deep dive into whether bremelanotide (PT-141) causes rebound effects after stopping, what the RECONNECT trial data show, and how to safely discontinue use.
Read clinical reviewA physician-reviewed deep dive into bremelanotide's effects on kidney function, covering pharmacokinetics, renal dosing guidance, clinical trial safety data from RECONNECT, and risk stratification for patients with CKD.
Read clinical reviewA clinician-level review of how seasonal factors, including light exposure, melatonin flux, mood shifts, and hormonal variation, affect PT-141 (bremelanotide) dosing, efficacy, and patient selection across the calendar year.
Read clinical reviewA physician-reviewed deep dive into how PT-141 (bremelanotide) affects sexual function in premenopausal women and men, covering the RECONNECT trials, melanocortin receptor pharmacology, dosing, side effects, and FDA approval status.
Read clinical reviewA clinician-level review of how PT-141 (bremelanotide) affects sleep architecture, including melanocortin signaling, polysomnographic data, REM and slow-wave sleep effects, and practical dosing guidance for patients using the drug around bedtime.
Read clinical reviewClinical guidance on using bremelanotide (PT-141) across time zones, managing jet lag effects on libido and dosing windows, storage during transit, and adjusting administration timing for HSDD and off-label use.
Read clinical reviewA clinician-level guide to safely restarting PT-141 (bremelanotide) after acute illness, covering pharmacology, dosing timelines, cardiovascular considerations, and RECONNECT trial data.
Read clinical reviewA clinician-reviewed, week-by-week guide to PT-141 (bremelanotide) for HSDD and off-label ED. Covers dosing, side effects, and realistic timelines from the RECONNECT trial.
Read clinical review